Madrigal Pharmaceuticals Inc.
MDGL | NASDAQ
$430.36
-$1.34 (-0.31%)
At close: Oct 30, 2026, 4:00 PM ET
$429.15
-$1.21 (-0.28%)
Pre-market:
Nov 2, 2026, 4:13 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 958.4M | 180.13M | n/a | n/a | n/a | n/a |
Cost of Revenue | 56.15M | 6.23M | n/a | n/a | n/a | 471K |
Gross Profit | 902.26M | 173.9M | n/a | n/a | n/a | -471K |
Operating Income | -300.1M | -497.88M | -380.5M | -293.57M | -242.48M | -206.32M |
Interest Income | 37.36M | 46.65M | 19.58M | 2.19M | 363K | 4.33M |
Pretax Income | -288.28M | -465.89M | -373.63M | -295.35M | -241.85M | -202.24M |
Net Income | -288.28M | -465.89M | -373.63M | -295.35M | -241.85M | -202.24M |
Selling & General & Admin | 813.83M | 435.06M | 108.15M | 48.13M | 37.32M | 21.86M |
Research & Development | 388.53M | 236.72M | 272.35M | 245.44M | 205.16M | 184.81M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 1.2B | 671.78M | 380.5M | 293.57M | 242.48M | 205.85M |
Interest Expense | 22.31M | 14.67M | 12.71M | 3.96M | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.26B | 678.01M | 380.5M | 293.57M | 242.48M | 206.67M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 22.43M | 21.27M | 18.69M | 17.14M | 16.54M | 15.45M |
Shares Outstanding (Diluted) | 22.43M | 21.27M | 18.69M | 17.14M | 16.54M | 15.45M |
EPS (Basic) | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 | -13.09 |
EPS (Diluted) | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 | -13.09 |
EBITDA | -264.47M | -450.13M | -360.39M | -290.92M | -241.44M | -201.77M |
EBIT | -265.98M | -451.22M | -360.92M | -291.39M | -241.85M | -202.24M |
Depreciation & Amortization | 1.51M | 1.1M | 527K | 467K | 405K | 471K |
Add to Watchlist
Select watchlists to add or remove MDGL